Advertisement
Screener

Lineage Cell Therapeutics, Inc. (LCTX) Beta

Lineage Cell Therapeutics, Inc. (LCTX) Beta

  • Beta · 5-year monthly: Value 1.55; Formula and calculation Saved five-year monthly beta; measures historical sensitivity to the benchmark..

Beta

Overview →

Financial period ending 2026-08-31; current quote 2026-08-31. Amounts retain their stated periods and units.

MetricValueFormula and calculation
Beta · 5-year monthly1.55Saved five-year monthly beta; measures historical sensitivity to the benchmark.

Calculated history

Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.

Period endingBeta
2026-08-311.55

(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aligos Therapeutics, Inc. (ALGS)United States$0.238B-0.47
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
Protalix BioTherapeutics, Inc. (PLX)$0.221B9.87
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37
Alector, Inc. (ALEC)United States$0.213B-1.90
Invivyd, Inc. (IVVD)United States$0.270B-2.42
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
FATE THERAPEUTICS INC (FATE)United States$0.280B-2.51